Prophylaxe der strahleninduzierten Diarrhö durch Smektit

Hombrink, J; Fröhlich, D.; Glatzel, M.; Krauß, Alexander; Thiel, Hans-Joachim; Meier, J; Hamann, Dörte; Mücke, Ralph; Glaser, Felix-Herbert; Köst, Sabine

doi:10.1007/s000660050053

Cited by 13 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A marked reduction in post-operative fecal score was observed when treated with DTO smectite. These findings are consistent with results of other clinical and research studies in horses (Herthel, 2000), dogs (Fioramonti et al, 1987), and people (Dupont et al, 1992;Vivatvakin et al, 1992;Madkour et al, 1993;Hombrink et al, 1995Hombrink et al, , 2000Milocco et al, 1999;Yao-Zong et al, 2004).…”

Section: Discussionsupporting

confidence: 90%

“…Several clinical trials in humans have demonstrated positive therapeutic effects of DTO smectite in the management of acute diarrhea in children (Dupont et al, 1992;Vivatvakin et al, 1992;Madkour et al, 1993;Milocco et al, 1999), chronic functional diarrhea in adults (Yao-Zong et al, 2004), and radiation-induced diarrhea in adults (Hombrink et al, 1995(Hombrink et al, , 2000. Therapy with DTO smectite is a mechanical approach to capturing bacterial endotoxins and exotoxins before they escape from the intestine and reach the systemic circulation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Di-tri-octahedral smectite for the prevention of post-operative diarrhea in equids with surgical disease of the large intestine: Results of a randomized clinical trial

Hassel

Smith

Nieto

et al. 2009

The Veterinary Journal

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Di-tri-octahedral smectite for the prevention of post-operative diarrhea in equids with surgical disease of the large intestine: Results of a randomized clinical trial

Hassel

Smith

Nieto

et al. 2009

The Veterinary Journal

View full text Add to dashboard Cite

“…It is also indicated in the prevention of radiation-induced, chemotherapy-induced, and acquired immune deficiency syndrome-associated chronic diarrhea. 34 35 36…”

Section: Absorbentmentioning

confidence: 99%

Pharmacologic Agents for Chronic Diarrhea

Lee

2015

Intest Res

View full text Add to dashboard Cite

Chronic diarrhea is usually associated with a number of non-infectious causes. When definitive treatment is unavailable, symptomatic drug therapy is indicated. Pharmacologic agents for chronic diarrhea include loperamide, 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists, diosmectite, cholestyramine, probiotics, antispasmodics, rifaximin, and anti-inflammatory agents. Loperamide, a synthetic opiate agonist, decreases peristaltic activity and inhibits secretion, resulting in the reduction of fluid and electrolyte loss and an increase in stool consistency. Cholestyramine is a bile acid sequestrant that is generally considered as the first-line treatment for bile acid diarrhea. 5-HT3 receptor antagonists have significant benefits in patients with irritable bowel syndrome (IBS) with diarrhea. Ramosetron improves stool consistency as well as global IBS symptoms. Probiotics may have a role in the prevention of antibiotic-associated diarrhea. However, data on the role of probiotics in the treatment of chronic diarrhea are lacking. Diosmectite, an absorbent, can be used for the treatment of chronic functional diarrhea, radiation-induced diarrhea, and chemotherapy-induced diarrhea. Antispasmodics including alverine citrate, mebeverine, otilonium bromide, and pinaverium bromide are used for relieving diarrheal symptoms and abdominal pain. Rifaximin can be effective for chronic diarrhea associated with IBS and small intestinal bacterial overgrowth. Budesonide is effective in both lymphocytic colitis and collagenous colitis. The efficacy of mesalazine in microscopic colitis is weak or remains uncertain. Considering their mechanisms of action, these agents should be prescribed properly.

show abstract

“…The acute gastrointestinal toxicity (diarrhea) of this combination seems to be higher in contrast to chemoradiation with cisplatin alone. There is no strong evidence for a benefit of prophylactic drug application to prevent this acute side effect [10].…”

Section: Introductionmentioning

confidence: 99%

Chemoradiation in Cervical Cancer with Cisplatin and High-Dose Rate Brachytherapy Combined with External Beam Radiotherapy

Strauß

Kuhnt

Laban

et al. 2002

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

show abstract

Prophylaxe der strahleninduzierten Diarrhö durch Smektit

Abstract: Prophylactic application of smectite during irradiation of the pelvis and the abdomen can delay the development of radiotherapy-induced diarrhea, a statistical significance could not be verified neither in the total study group nor in the post-hoc subgroup analysis.

Cited by 13 publications

References 15 publications

Di-tri-octahedral smectite for the prevention of post-operative diarrhea in equids with surgical disease of the large intestine: Results of a randomized clinical trial

Di-tri-octahedral smectite for the prevention of post-operative diarrhea in equids with surgical disease of the large intestine: Results of a randomized clinical trial

Pharmacologic Agents for Chronic Diarrhea

Chemoradiation in Cervical Cancer with Cisplatin and High-Dose Rate Brachytherapy Combined with External Beam Radiotherapy

Contact Info

Product

Resources

About